Trial Profile
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Gastric 100
- Sponsors EMD Serono; Merck KGaA
- 23 Jun 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2021 Planned End Date changed from 31 Mar 2021 to 4 Jun 2021.
- 28 Jan 2021 Planned End Date changed from 11 Mar 2024 to 31 Mar 2021.